Notice of Filing Securities Class Action Against Immucor and Certain of Its Former and Current Officers

Lerach Coughlin Stoia Geller Rudman & Robbins LLP
("Lerach Coughlin") (http://www.lerachlaw.com/cases/Immucor/) today
announced that a class action has been commenced in the United States
District Court for the Northern District of Georgia on behalf of
purchasers of Immucor, Inc. ("Immucor") (NASDAQ:BLUDE) common stock
during the period between January 7, 2005 and August 29, 2005 (the
"Class Period").
   If you wish to serve as lead plaintiff, you must move the Court no
later than 60 days from August 31, 2005. If you wish to discuss this
action or have any questions concerning this notice or your rights or
interests, please contact plaintiff's counsel, William Lerach or
Darren Robbins of Lerach Coughlin at 800/449-4900 or 619/231-1058, or
via e-mail at [e-mail], or at 401 B Street, Suite 1600, San
Diego, CA 92101. If you are a member of this class, you can view a
copy of the complaint as filed or join this class action online at
http://www.lerachlaw.com/cases/Immucor/. Any member of the purported
class may move the Court to serve as lead plaintiff through counsel of
their choice, or may choose to do nothing and remain an absent class
member.
   The complaint charges Immucor and certain of its officers and
directors with violations of the Securities Exchange Act of 1934.
   During the Class Period, defendants caused Immucor's shares to
trade at artificially inflated levels by issuing a series of
materially false and misleading statements regarding the Company's
financial statements, business and prospects. This caused the
Company's stock to trade as high as $34.98 per share. Defendants took
advantage of this artificial inflation selling 139,500 shares of their
Immucor stock for proceeds of $4.2 million.
   On August 26, 2005, Immucor announced a formal Securities and
Exchange Commission investigation into payments made by Immucor's
Italian subsidiary in October 2003 to a physician connected to a
hospital with which Immucor did business.
   Then, on August 29, 2005, after the market closed, the Company
announced that it had revised its net income for fiscal 2005 to
account for a previously unrecorded accrual for employee bonuses and
furthermore made an announcement that it had accepted the resignation
of defendant Steven Ramsey from the post of Chief Financial Officer.
   On this news, Immucor's stock collapsed to as low as $22.67 per
share before closing at $24 per share on volume of 6.2 million shares.
   Plaintiff seeks to recover damages on behalf of all purchasers of
Immucor common stock during the Class Period (the "Class").